Fig 2: Verification of knockdown of SPARC expression in highly invasive cell line S1 and HO8910PM by lentivirus-mediated RNA interference.(A) SPARC protein expression in lentivirus-infected cells as measured by Western blot. (B) SPARC mRNA expression in lentivirus-infected cells as measured by q-RT-PCR. (C) SPARC protein expression in lentivirus-infected cells as measured by IHC staining (Magnification ×200). *P<0.05 versus control.

Fig 3: Expression of SPARC in human ovarian tissues using antibody AF941 and bs-1133R.(A) Normal human ovarian tissue using antibody AF941, (B) Benign ovarian tumor using antibody AF941, (C) High differentiation of ovarian carcinoma using antibody AF941, (D) Medium differentiation of ovarian carcinoma using antibody AF941, (E) Low differentiation of ovarian carcinoma using antibody AF941, (F) Normal human ovarian tissue using antibody bs-1133R, (G) Benign ovarian tumor using antibody bs-1133R, (H) High differentiation of ovarian carcinoma using antibody bs-1133R, (I) Medium differentiation of ovarian carcinoma using antibody bs-1133R, (J) Low differentiation of ovarian carcinoma using antibody bs-1133R (Magnification ×200). Black arrows indicate cell cytoplasm stained, red arrows indicate stroma stained.

Fig 4: The downstream target genes of SPARC in affecting ovarian cancer cell proliferation, apoptosis and invasion.(A) The downstream target genes of SPARC as measured by q-RT-PCR. (B) P53, P21, Cyclin D1, PCNA, Bcl–2 and Bax protein expression in lentivirus-infected cells as measured by Western blot. (C) E-cardherin protein expression in lentivirus-infected cells as measured by IHC staining (Magnification ×200). (D) MMPs activities measured by zymography. *P<0.05 versus control.

Fig 5: Peptide blocking assay with recombinant Human SPARC.(A) Normal human ovarian tissue, (B) Benign ovarian tumor, (C) High differentiation of ovarian carcinoma, (D) Medium differentiation of ovarian carcinoma, (E) Low differentiation of ovarian carcinoma (Magnification ×200). (F) Kaplan-Meier analysis about the overall survival of the patients whose tumors had high or low SPARC expression.